- Home
- EBS vs TSHA Comparison
EBS vs TSHA Comparison
Compare EBS & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EBS
- TSHA
- Stock Information
- Founded
- EBS 1998
- TSHA 2019
- Country
- EBS United States
- TSHA United States
- Employees
- EBS N/A
- TSHA N/A
- Industry
- EBS Biotechnology: Pharmaceutical Preparations
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- EBS Health Care
- TSHA Health Care
- Exchange
- EBS Nasdaq
- TSHA Nasdaq
- Market Cap
- EBS 459.6M
- TSHA 403.7M
- IPO Year
- EBS 2006
- TSHA 2020
- Fundamental
- Price
- EBS $8.09
- TSHA $1.85
- Analyst Decision
- EBS Strong Buy
- TSHA Strong Buy
- Analyst Count
- EBS 2
- TSHA 8
- Target Price
- EBS $14.00
- TSHA $6.63
- AVG Volume (30 Days)
- EBS 999.1K
- TSHA 4.9M
- Earning Date
- EBS 11-06-2024
- TSHA 11-13-2024
- Dividend Yield
- EBS N/A
- TSHA N/A
- EPS Growth
- EBS N/A
- TSHA N/A
- EPS
- EBS N/A
- TSHA N/A
- Revenue
- EBS $1,125,500,000.00
- TSHA $9,915,000.00
- Revenue This Year
- EBS $6.64
- TSHA N/A
- Revenue Next Year
- EBS $7.95
- TSHA N/A
- P/E Ratio
- EBS N/A
- TSHA N/A
- Revenue Growth
- EBS 2.05
- TSHA N/A
- 52 Week Low
- EBS $1.42
- TSHA $1.19
- 52 Week High
- EBS $15.10
- TSHA $4.32
- Technical
- Relative Strength Index (RSI)
- EBS 39.08
- TSHA 38.54
- Support Level
- EBS $8.35
- TSHA $1.80
- Resistance Level
- EBS $8.86
- TSHA $2.72
- Average True Range (ATR)
- EBS 0.50
- TSHA 0.23
- MACD
- EBS -0.11
- TSHA -0.10
- Stochastic Oscillator
- EBS 17.58
- TSHA 3.81
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.